FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896471641> ?p ?o ?g. }

• W2896471641 endingPage "361" @default.
• W2896471641 startingPage "357" @default.
• W2896471641 abstract "The LVIS stent system (LVIS and LVIS Junior) is a self-expanding, retrievable, microstent system indicated for the treatment of wide-necked cerebral aneurysms (WNAs). The present pivotal study was performed to evaluate the safety and effectiveness of this device.The US LVIS pivotal trial was a prospective, multicenter, single-arm, interventional study conducted at 21 US centers. The study enrolled 153 adults with WNAs of the anterior and posterior circulations. The study was conducted under good clinical practices and included independent adjudication of all adverse events. The primary effectiveness endpoint was defined as successful aneurysm treatment with the LVIS System as evidenced by complete (100%) aneurysm occlusion at 12 months on conventional angiography without retreatment and without significant (≥50%) stenosis of the treated artery at 12 months as determined by an independent core laboratory. The primary safety endpoint was defined as the rate of stroke or death within 30 days, or ipsilateral stroke or neurologic death with 12 months.One hundred and fifty-three patients enrolled at 21 investigational sites underwent attempted LVIS-assisted coil embolization. The mean age was 58.3±10.5 years and the majority of the participants (110/153, 71.9%) were female. Fifty-seven aneurysms (57/153, 37.3%) arose from the anterior cerebral artery, 43 (43/153, 28.1%) from the internal carotid artery, 17 (17/153, 11.1%) from the middle cerebral artery, 27 (27/153, 17.6%) from the basilar artery, six (6/153,3.9 %) from the PCA, and two from the vertebral artery. A single aneurysm arose from the superior cerebellar artery. The mean aneurysm dome height was 6.0±2.2 mm and mean width 5.5±2.3 mm. Mean neck width was 4.2±1.4 mm. A total of 22 participants presented for re-treatment of a previously ruptured (>30 days prior to treatment) target aneurysm. The primary effectiveness endpoint was observed in 70.6% (108/153) in the intent to treat population (ITT). Of the evaluable participants with follow-up 12-month angiography, 79.1 % (110/139) demonstrated complete occlusion- 92.1% (128/139) in this population demonstrated ≥95% occlusion and 95% demonstrated ≥90% occlusion (132/139). Eight participants (5.2%, 8/153) had at least one primary safety event in the ITT population.The LVIS stent system allows safe and highly effective coil embolization of WNAs.NCT01793792." @default.
• W2896471641 created "2018-10-26" @default.
• W2896471641 creator A5006528562 @default.
• W2896471641 creator A5015284369 @default.
• W2896471641 creator A5037816826 @default.
• W2896471641 creator A5040981639 @default.
• W2896471641 creator A5042641612 @default.
• W2896471641 creator A5058413004 @default.
• W2896471641 creator A5062117153 @default.
• W2896471641 date "2018-10-08" @default.
• W2896471641 modified "2023-10-17" @default.
• W2896471641 title "The safety and effectiveness of the LVIS stent system for the treatment of wide-necked cerebral aneurysms: final results of the pivotal US LVIS trial" @default.
• W2896471641 cites W1521631692 @default.
• W2896471641 cites W1728088773 @default.
• W2896471641 cites W1972169575 @default.
• W2896471641 cites W1984096471 @default.
• W2896471641 cites W1986520093 @default.
• W2896471641 cites W2015805110 @default.
• W2896471641 cites W2022104261 @default.
• W2896471641 cites W2034729841 @default.
• W2896471641 cites W2049347141 @default.
• W2896471641 cites W2093316689 @default.
• W2896471641 cites W2097729692 @default.
• W2896471641 cites W2098855020 @default.
• W2896471641 cites W2107140167 @default.
• W2896471641 cites W2113125070 @default.
• W2896471641 cites W2150560716 @default.
• W2896471641 cites W2158147889 @default.
• W2896471641 cites W2403852285 @default.
• W2896471641 cites W2408682253 @default.
• W2896471641 cites W2509254458 @default.
• W2896471641 cites W2531760180 @default.
• W2896471641 cites W2540523011 @default.
• W2896471641 cites W2742502391 @default.
• W2896471641 cites W2770830624 @default.
• W2896471641 cites W2788479770 @default.
• W2896471641 cites W2800286861 @default.
• W2896471641 cites W2807379832 @default.
• W2896471641 doi "https://doi.org/10.1136/neurintsurg-2018-014309" @default.
• W2896471641 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6582711" @default.
• W2896471641 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30297543" @default.
• W2896471641 hasPublicationYear "2018" @default.
• W2896471641 type Work @default.
• W2896471641 sameAs 2896471641 @default.
• W2896471641 citedByCount "47" @default.
• W2896471641 countsByYear W28964716412019 @default.
• W2896471641 countsByYear W28964716412020 @default.
• W2896471641 countsByYear W28964716412021 @default.
• W2896471641 countsByYear W28964716412022 @default.
• W2896471641 countsByYear W28964716412023 @default.
• W2896471641 crossrefType "journal-article" @default.
• W2896471641 hasAuthorship W2896471641A5006528562 @default.
• W2896471641 hasAuthorship W2896471641A5015284369 @default.
• W2896471641 hasAuthorship W2896471641A5037816826 @default.
• W2896471641 hasAuthorship W2896471641A5040981639 @default.
• W2896471641 hasAuthorship W2896471641A5042641612 @default.
• W2896471641 hasAuthorship W2896471641A5058413004 @default.
• W2896471641 hasAuthorship W2896471641A5062117153 @default.
• W2896471641 hasBestOaLocation W28964716411 @default.
• W2896471641 hasConcept C126322002 @default.
• W2896471641 hasConcept C126838900 @default.
• W2896471641 hasConcept C127413603 @default.
• W2896471641 hasConcept C141071460 @default.
• W2896471641 hasConcept C168563851 @default.
• W2896471641 hasConcept C203092338 @default.
• W2896471641 hasConcept C2775841333 @default.
• W2896471641 hasConcept C2776098176 @default.
• W2896471641 hasConcept C2777031167 @default.
• W2896471641 hasConcept C2778333808 @default.
• W2896471641 hasConcept C2778583881 @default.
• W2896471641 hasConcept C2780007028 @default.
• W2896471641 hasConcept C2780405337 @default.
• W2896471641 hasConcept C2780643987 @default.
• W2896471641 hasConcept C2780645631 @default.
• W2896471641 hasConcept C2781012200 @default.
• W2896471641 hasConcept C541997718 @default.
• W2896471641 hasConcept C71924100 @default.
• W2896471641 hasConcept C78519656 @default.
• W2896471641 hasConceptScore W2896471641C126322002 @default.
• W2896471641 hasConceptScore W2896471641C126838900 @default.
• W2896471641 hasConceptScore W2896471641C127413603 @default.
• W2896471641 hasConceptScore W2896471641C141071460 @default.
• W2896471641 hasConceptScore W2896471641C168563851 @default.
• W2896471641 hasConceptScore W2896471641C203092338 @default.
• W2896471641 hasConceptScore W2896471641C2775841333 @default.
• W2896471641 hasConceptScore W2896471641C2776098176 @default.
• W2896471641 hasConceptScore W2896471641C2777031167 @default.
• W2896471641 hasConceptScore W2896471641C2778333808 @default.
• W2896471641 hasConceptScore W2896471641C2778583881 @default.
• W2896471641 hasConceptScore W2896471641C2780007028 @default.
• W2896471641 hasConceptScore W2896471641C2780405337 @default.
• W2896471641 hasConceptScore W2896471641C2780643987 @default.
• W2896471641 hasConceptScore W2896471641C2780645631 @default.
• W2896471641 hasConceptScore W2896471641C2781012200 @default.
• W2896471641 hasConceptScore W2896471641C541997718 @default.
• W2896471641 hasConceptScore W2896471641C71924100 @default.
• W2896471641 hasConceptScore W2896471641C78519656 @default.
• W2896471641 hasIssue "4" @default.

• next